IS5009A - 3-Alkoxýísoxazól-4-ýl setin 2-amínó karboxýlsýru efnasambönd - Google Patents

3-Alkoxýísoxazól-4-ýl setin 2-amínó karboxýlsýru efnasambönd

Info

Publication number
IS5009A
IS5009A IS5009A IS5009A IS5009A IS 5009 A IS5009 A IS 5009A IS 5009 A IS5009 A IS 5009A IS 5009 A IS5009 A IS 5009A IS 5009 A IS5009 A IS 5009A
Authority
IS
Iceland
Prior art keywords
alkoxyisoxazol
substituted
carboxylic acid
acid compounds
amino carboxylic
Prior art date
Application number
IS5009A
Other languages
English (en)
Inventor
Bang-Andersen Benny
Peter Bøgesø Klaus
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of IS5009A publication Critical patent/IS5009A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS5009A 1996-10-04 1999-03-23 3-Alkoxýísoxazól-4-ýl setin 2-amínó karboxýlsýru efnasambönd IS5009A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK109296 1996-10-04
PCT/DK1997/000426 WO1998015542A1 (en) 1996-10-04 1997-10-03 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds

Publications (1)

Publication Number Publication Date
IS5009A true IS5009A (is) 1999-03-23

Family

ID=8100908

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5009A IS5009A (is) 1996-10-04 1999-03-23 3-Alkoxýísoxazól-4-ýl setin 2-amínó karboxýlsýru efnasambönd

Country Status (26)

Country Link
US (1) US6200999B1 (is)
EP (1) EP0934286B1 (is)
JP (1) JP2001501630A (is)
KR (1) KR20000048908A (is)
CN (1) CN1238766A (is)
AR (1) AR008880A1 (is)
AT (1) ATE230734T1 (is)
AU (1) AU733004B2 (is)
BG (1) BG103348A (is)
BR (1) BR9712198A (is)
CA (1) CA2268028C (is)
CZ (1) CZ116899A3 (is)
DE (1) DE69718338T2 (is)
EA (1) EA001625B1 (is)
ES (1) ES2189978T3 (is)
HU (1) HUP0000084A3 (is)
IL (1) IL129135A0 (is)
IS (1) IS5009A (is)
NO (1) NO312961B1 (is)
NZ (1) NZ334798A (is)
PL (1) PL332553A1 (is)
SK (1) SK42899A3 (is)
TR (1) TR199900724T2 (is)
UA (1) UA52698C2 (is)
WO (1) WO1998015542A1 (is)
ZA (1) ZA978877B (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73749C2 (en) * 1999-11-01 2005-09-15 Diarylenines
DE60122176T2 (de) * 2000-09-15 2007-07-05 Vertex Pharmaceuticals Inc., Cambridge Isoxazole und ihre verwendung als erk-inhibitoren
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
UA78529C2 (en) * 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
WO2004092189A1 (en) 2003-04-09 2004-10-28 Wyeth Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists
TW200514775A (en) 2003-10-22 2005-05-01 Wyeth Corp Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof
CN101277952B (zh) * 2005-10-11 2011-09-28 弗·哈夫曼-拉罗切有限公司 异*唑衍生物
US8722714B2 (en) 2008-01-16 2014-05-13 The Honk Kong University of Science and Technology Oxazolidine derivatives as NMDA antagonists
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物
US10442768B2 (en) 2016-01-21 2019-10-15 Agro-Kanesho Co., Ltd. Method for producing 2-aminonicotinic acid benzyl ester derivative

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE108448T1 (de) 1990-05-11 1994-07-15 Sankyo Co Piperdinyloxy- und chinindidinyloxy- isoxazol- derivate, ihre herstellung und ihre therapeutische verwendung.
AU678186B2 (en) 1992-10-23 1997-05-22 Merck Sharp & Dohme Limited Dopamine receptor subtype ligands
DK124393D0 (da) * 1993-11-03 1993-11-03 Lundbeck & Co As H Compounds

Also Published As

Publication number Publication date
EA199900358A1 (ru) 1999-10-28
CN1238766A (zh) 1999-12-15
NO991561D0 (no) 1999-03-30
NO991561L (no) 1999-06-04
IL129135A0 (en) 2000-02-17
ES2189978T3 (es) 2003-07-16
EA001625B1 (ru) 2001-06-25
CA2268028C (en) 2003-03-18
ZA978877B (en) 1998-04-17
EP0934286A1 (en) 1999-08-11
CA2268028A1 (en) 1998-04-16
AR008880A1 (es) 2000-02-23
EP0934286B1 (en) 2003-01-08
NZ334798A (en) 2000-06-23
PL332553A1 (en) 1999-09-13
HUP0000084A3 (en) 2001-12-28
BG103348A (en) 1999-11-30
DE69718338T2 (de) 2003-10-16
NO312961B1 (no) 2002-07-22
UA52698C2 (uk) 2003-01-15
ATE230734T1 (de) 2003-01-15
HUP0000084A2 (hu) 2000-06-28
AU733004B2 (en) 2001-05-03
KR20000048908A (ko) 2000-07-25
BR9712198A (pt) 1999-08-31
AU4451797A (en) 1998-05-05
SK42899A3 (en) 1999-08-06
CZ116899A3 (cs) 1999-09-15
US6200999B1 (en) 2001-03-13
WO1998015542A1 (en) 1998-04-16
DE69718338D1 (de) 2003-02-13
JP2001501630A (ja) 2001-02-06
TR199900724T2 (xx) 1999-06-21

Similar Documents

Publication Publication Date Title
DE59601770D1 (de) Substituierte quaterrylentetracarbonsäurediimide
DE69703385D1 (de) Alkoxyessigsäure-derivate
NO990821D0 (no) Arylsulfonylamino-hydroksaminsyre-derivater
ATE228995T1 (de) Aminomethylcarbonsäurederivate
PT925298E (pt) Derivados 6,6-hetero-biciclicos substituidos
ATE269861T1 (de) Substituierte indolalkansäure
TR199802106A3 (tr) Sübstitüe edilmis izokinolin-3-karbon asidi amidleri.
ATE248812T1 (de) Arylsulfonylhydroxamsäurederivate
DK1003720T3 (da) Aryloxyarylsulfonylaminohydroxamsyrederivater
FI945688A7 (fi) Etikkahappojohdannaisia
DK1179533T3 (da) Salt af naphthyridincarboxylsyrederivat
FI934411L (fi) Kinolonkarboxylsyror
DE69606053D1 (de) Modifizierte fluorsulfonsäure
FI944045L (fi) Aromaattisia karboksyylihappojohdannaisia
FI950586A7 (fi) Aminohappojohdos
DE59801919D1 (de) Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
NO991561D0 (no) 3-alkoksyisoksazol-4-yl-substituerte 2-aminokarboksylsyreforbindelser
DE59707658D1 (de) Glyoxylsäure-derivate
ID17938A (id) Penghambatan metalloproreinase-metalloproteinase oleh asam-asam 2-(w-aroilalkil)-4-biaril-4-oksobutirat
NO306159B1 (no) 5-arylisoksazol-4-substituerte 2-aminokarboksylsyreforbindelser
FI970195L (fi) Trifluormetyylikinoliinikarboksyylihappojohdannainen
BR9610139A (pt) Derivado de ácido carboxílico
FI940040L (fi) Nonatetraeenihappojohdannainen
EE200000239A (et) Uued metüleenbisfosfoonhappe derivaadid
DE69822338D1 (de) Polyisobuten substituierte bernsteinsäureimide